Special Drug Use-results Survey for Long-term Use (Fostamatinib)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: fostamatinib.
- Who it may be relevant to
- Registry conditions: Chronic Idiopathic Thrombocytopenic Purpura. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Japan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Detailed description
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Interventions
- Drug fostamatinib
oral administration
Primary outcome measures
- Adverse events [Time frame: 18 months]
Eligibility criteria
Inclusion criteria
- Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Japan · 1 center
- Research site — Tokyo and Japanese Other Cities
Identifiers
NCT: NCT06757257 · TLPMS01